For research use only. Not for therapeutic Use.
Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM[1].
Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice[1].
Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice[1].
| Catalog Number | I019076 |
| CAS Number | 1883528-69-5 |
| Synonyms | 2-[(2-ethylphenyl)methoxy]-N-pyridin-3-ylbenzamide |
| Molecular Formula | C21H20N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H20N2O2/c1-2-16-8-3-4-9-17(16)15-25-20-12-6-5-11-19(20)21(24)23-18-10-7-13-22-14-18/h3-14H,2,15H2,1H3,(H,23,24) |
| InChIKey | YRUSTWBJNUPPQI-UHFFFAOYSA-N |
| SMILES | CCC1=CC=CC=C1COC2=CC=CC=C2C(=O)NC3=CN=CC=C3 |
| Reference | [1]. Li Y, et al. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor. Eur J Med Chem. 2019 Feb 1;163:864-882. |
